Venom Immunotherapy in Clinical Practice: A Retrospective Real-World Cohort
Toxins · 2026
DOI: 10.3390/toxins18100447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2026. Verfasst von İsmet Bulut und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul 34403, Turkey. Hauptthemen laut MEDLINE: Venom Hypersensitivity, Desensitization, Immunologic, Bee Venoms, Wasp Venoms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Venom immunotherapy (VIT) is the only disease-modifying treatment for Hymenoptera venom allergy, but real-world data describing VIT-related reactions and individualized premedication practices remain limited. We retrospectively evaluated 16 adults undergoing VIT with a target maintenance dose of 100 µg administered every 4 weeks at a tertiary allergy center between January 2024 and December 2025, focusing on clinical characteristics, premedication, treatment-related reactions, and field-sting outcomes during follow-up of up to 24 months. All patients had severe index reactions (Müller grade III-IV); 13 (81.3%) received Vespula VIT and 3 (18.8%) honey bee VIT. Premedication was initiated before VIT in seven patients (43.8%), including omalizumab in five (31.3%). During the 7-week up-dosing phase, five patients (31.3%) developed local reactions, whereas no systemic reactions occurred (0/16; 95% CI: 0–20.6%). During maintenance, one systemic reaction occurred (6.3%), requiring adrenaline and one-night intensive care admission, after which VIT was discontinued. Two patients were re-stung during follow-up and developed only local reactions. In this small, selected real-world cohort, no systemic reactions were observed during the up-dosing phase, whereas one systemic reaction occurred during maintenance. Given the limited sample size, wide confidence intervals, and frequent use of individualized premedication, these findings should be interpreted as descriptive observations and not as evidence establishing the safety of VIT or the effectiveness of premedication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul 34403, Turkey.
- Department of Emergency Medicine, Tuzla State Hospital, Istanbul 34403, Turkey.
- Department of Emergency Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, Turkey.
ORCID-Profile: Zeynep Yegin Katran
Zitieren
APA
Bulut, İ., Katran, Z. Y., Argın, Ö., Katran, M., & Çakmak, F. (2026). Venom Immunotherapy in Clinical Practice: A Retrospective Real-World Cohort. Toxins. https://doi.org/10.3390/toxins18100447
Vancouver
Bulut İ, Katran ZY, Argın Ö, Katran M, Çakmak F. Venom Immunotherapy in Clinical Practice: A Retrospective Real-World Cohort. Toxins. 2026. doi:10.3390/toxins18100447
BibTeX
@article{Bulut2026,
author = {Bulut, İsmet and Katran, Zeynep Yegin and Argın, Özge and Katran, Mustafa and Çakmak, Fatma},
title = {Venom Immunotherapy in Clinical Practice: A Retrospective Real-World Cohort},
journal = {Toxins},
year = {2026},
doi = {10.3390/toxins18100447}
}
EUVIMED